Article

Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Seminars in Oncology (impact factor: 3.5). 03/2006; 33(1 Suppl 3):S17-20. DOI:10.1053/j.seminoncol.2005.12.018 pp.S17-20
Source: PubMed

ABSTRACT A wide variety of cutaneous T-cell lymphoma therapies are now used in clinical practice. Treatment options include phototherapy, radiation, topical therapy, systemic mono-chemotherapy, combination chemotherapy, and combined modalities. Many patients fail or develop resistance to monotherapy, resulting in a need for combined treatment modalities to improve therapeutic results in terms of quality of life and duration of response. Recently, bexarotene, a selective antagonist of the retinoid X receptor, has been approved in the treatment of patients with cutaneous T-cell lymphoma. Bexarotene offers new opportunities for combination treatment strategies because of its novel and unique mechanism of action. In this article we review the rationale and examine key published evidence on combining these new treatment modalities.

0 0
 · 
0 Bookmarks
 · 
15 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Bexarotene
 
clinical practice
 
combination chemotherapy
 
combination treatment strategies
 
cutaneous T-cell lymphoma
 
cutaneous T-cell lymphoma therapies
 
modalities
 
monotherapy
 
new opportunities
 
new treatment modalities
 
patients
 
phototherapy
 
retinoid X receptor
 
selective antagonist
 
systemic mono-chemotherapy
 
topical therapy
 
treatment modalities
 
Treatment options
 
unique mechanism
 
wide variety